

# **QCDR Measure:**

AAO-21: Ocular Myasthenia Gravis: Improvement of ocular deviation or absence of diplopia or functional improvement

# **National Quality Strategy Domain:**

Effective Clinical Care

# Measure Type:

Outcome

# **Description:**

Percentage of patients with a diagnosis of ocular myasthenia gravis who had an improvement of ocular deviation OR were absent of diplopia in primary gaze OR had functional improvement of ptosis 6 months after initial treatment.

### Instructions:

This measure is to be reported a minimum of <u>once per reporting period</u> for patients diagnosed with ocular myasthenia gravis between January 1 and June 30. It is anticipated that clinicians who provide the primary management of patients with ocular myasthenia gravis will submit this measure.

#### **Denominator:**

All patients aged 18 years or older diagnosed with ocular myasthenia gravis between January 1 and June 30 of the reporting period and received treatment for the condition.

#### **Denominator Criteria**

Patients aged ≥ 18 years

AND

Two or more encounters within the last 6 months (CPT: 99201, 99202, 99203, 99204, 99205, 99244, 99245, 92002, 92004, 92012, 92014, 99212, 99213, 99214, 99215)

AND

### Diagnosis of ocular myasthenia gravis

- Myasthenia gravis without (acute) exacerbation (ICD-10: G70.00)
- Myasthenia gravis with (acute) exacerbation (ICD-10: G70.01)

AND

Ptosis and/or diplopia

- Unspecified ptosis of eyelid (ICD-10: H02.401, H02.402, H02.403, H02.409)
- Myogenic ptosis of eyelid (ICD-10: H02.421, H02.422, H02.423, H02.429)
- Diplopia (ICD-10: H53.2)

## AND

#### Treatment initiated

- Patient prescribed one of the following medications pyridostigmine, prednisone, mycophenolate mofetil, azathioprine, cyclosporine, rituximab.
- Strabismus surgery (CPT: 67311, 67312, 67314, 67316, 67318)
- Repair of blepharoptosis (CPT: 67901, 67902, 67903, 67904, 67906, 67908)
- Extraocular muscle procedure (CPT: 67345)
- Press-on prism (HCPCS: V2718)
- Occluder lens (HCPCS: V2770)

# **Numerator:**

Patients with improvement of ocular deviation or absence of diplopia in primary gaze after treatment or functional improvement of ptosis at 6 months

# **Numerator Options:**

Performance Met: Patient had an improvement in ocular deviation 6 months

after initial treatment.

OR

Patient had absence of diplopia in primary gaze 6 months

after initial treatment.

OR

Patient had a functional improvement of ptosis 6 months

after initial treatment.

Performance Not Met: Patient did not meet any of the performance criteria

# **Improvement Notation:**

Higher score indicates better performance